Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Up 0.6% – What’s Next?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)’s share price rose 0.6% during trading on Monday . The stock traded as high as $3.36 and last traded at $3.29. Approximately 33,873 shares traded hands during trading, a decline of 52% from the average daily volume of 70,291 shares. The stock had previously closed at $3.27.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Kiora Pharmaceuticals in a research report on Tuesday, November 12th.

Kiora Pharmaceuticals Price Performance

The business has a fifty day moving average of $3.48 and a 200-day moving average of $4.03.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.09. On average, analysts anticipate that Kiora Pharmaceuticals, Inc. will post 0.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC bought a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals makes up 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 16th biggest position. Stonepine Capital Management LLC owned 6.86% of Kiora Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.